TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22588577

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral sex therapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral sex therapy with ginkgo biloba
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral sex therapy without ginkgo biloba
Number of subjects: 31
Study: 21834061

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: MTX in combination with TNF inhibitors
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: TNF inhibitors as monotherapy
Number of subjects: 505

Group type: COMPARATOR
Intervention: Control group (SpA patients receiving NSAIDs/analgesics)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Concomitant prednisolone treatment
Number of subjects: 505
Study: 19726822

Group type: EXPERIMENTAL
Intervention: Ionic high‐osmolar radiographic contrast agent diatrizoate (Group A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non‐ionic iso‐osmolar contrast agent iodixanol (Group B)
Number of subjects: 44
Study: 17461857

Group type: EXPERIMENTAL
Intervention: Alovudine 2 mg/day
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Alovudine 1 mg/day
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 15651747

Group type: COMPARATOR
Intervention: stavudine/didanosine/efavirenz (group A)
Number of subjects: 161

Group type: COMPARATOR
Intervention: zidovudine/lamivudine/nelfinavir (group B)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: alternating regimen (group C)
Number of subjects: 161
Study: 11269571

Group type: EXPERIMENTAL
Intervention: RG 12525 100 mg qd for 4 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RG 12525 600 mg qd for 4 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 0
Study: 9051276

Group type: EXPERIMENTAL
Intervention: Information-eliciting strategies (interviewing styles and question types)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: External validation of body-related attitudes
Number of subjects: 80
Study: 7958164

Group type: EXPERIMENTAL
Intervention: buserelin (1.2 mg/day, intranasally for 3 months)
Number of subjects: 12
Study: 2885599

Group type: EXPERIMENTAL
Intervention: Prednisolone (40 mg daily for the first week, tapering off over 2 weeks)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 78
Study: 28497396

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Training (PMRT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Training (PMRT) plus Chinese Medicine Five-Element Music Therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (PMRT only)
Number of subjects: 60
Study: 27543208

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: MI intervention with HealthCall
Number of subjects: 230

Group type: COMPARATOR
Intervention: Educational intervention
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Exploratory outcomes (drinking frequency, binge frequency, maximum quantity)
Number of subjects: 230
Study: 23538559

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 45
Study: 23687260

Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 606

Group type: COMPARATOR
Intervention: INX
Number of subjects: 606
Study: 21208550

Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted split H1N1 vaccine
Number of subjects: 347

Group type: COMPARATOR
Intervention: Whole-virion (WV) vaccine
Number of subjects: 347
Study: 18188748

Group type: EXPERIMENTAL
Intervention: Tobacco-free snuff
Number of subjects: 106

Group type: COMPARATOR
Intervention: No snuff
Number of subjects: 106
Study: 16157857

Group type: EXPERIMENTAL
Intervention: Brace only
Number of subjects: 67

Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Combination brace and physical therapy
Number of subjects: 67
Study: 11955605

Group type: EXPERIMENTAL
Intervention: Cochlear implant children
Number of subjects: 240

Group type: COMPARATOR
Intervention: Normal-hearing children
Number of subjects: 240
Study: 9917226

Group type: EXPERIMENTAL
Intervention: L-754,030 (400 mg before cisplatin and 300 mg on days 2 to 5)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: L-754,030 (400 mg before cisplatin and placebo on days 2 to 5)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo (before cisplatin and placebo on days 2 to 5)
Number of subjects: 159
Study: 7793188

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 74

Group type: COMPARATOR
Intervention: Thiamylal-isoflurane
Number of subjects: 74
Study: 1962596

Group type: EXPERIMENTAL
Intervention: Droloxifene 20 mg once a day
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg once a day
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Droloxifene 80 mg once a day
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Droloxifene 120 mg once a day (pilot study)
Number of subjects: 94
Study: 7060371

Group type: EXPERIMENTAL
Intervention: 300 μg norethisterone (NET) minipill
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50 μg of ethinylestradiol for 7 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: norethisterone
Number of subjects: 24
Study: 30396772

Group type: EXPERIMENTAL
Intervention: Iso-osmolar oral supplement (279 mOsm/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hyperosmolar oral supplement (681 mOsm/kg)
Number of subjects: 8
Study: 28235537

Group type: EXPERIMENTAL
Intervention: Desflurane 4.1% with remifentanil 1ng/ml (R1 group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Desflurane 3.4% with remifentanil 3ng/ml (R3 group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: R1 group (1ng/ml of remifentanil)
Number of subjects: 42

Group type: COMPARATOR
Intervention: R3 group (3ng/ml of remifentanil)
Number of subjects: 42
Study: 27923389

Group type: EXPERIMENTAL
Intervention: Slow infusion of 5% albumin (180 minutes) at a dose of 10 ml/kg ideal body weight
Number of subjects: 70

Group type: COMPARATOR
Intervention: Rapid infusion of 5% albumin (30 minutes) at a dose of 10 ml/kg ideal body weight
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both rapid and slow infusion of 5% albumin
Number of subjects: 70
Study: 24438432

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for 4 weeks
Number of subjects: 70
Study: 22374642

Group type: EXPERIMENTAL
Intervention: 0.2 units/kg aspart
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 0.4 units/kg detemir
Number of subjects: 8

Group type: COMPARATOR
Intervention: Separate injection of aspart and detemir
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mixed injection of aspart and detemir
Number of subjects: 8
Study: 19319701

Group type: EXPERIMENTAL
Intervention: Prophylactic antiepileptic drugs (AEDs) initiated in 23 patients (8%) without documented seizure during the first 10 days of the trial.
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo (control group from the Cerebral Hemorrhage and NXY‐059 Trial).
Number of subjects: 295
Study: 17000884

Group type: EXPERIMENTAL
Intervention: Enoxaparin 1.0 mg/kg every 12 hours for 5 days, followed by 1.0 mg/kg daily for 175 days
Number of subjects: 122

Group type: COMPARATOR
Intervention: Enoxaparin 1.0 mg/kg every 12 hours for at least 5 days followed by warfarin (stable INR of 2 to 3)
Number of subjects: 122
Study: 12491503

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m(2)) followed by paclitaxel (175 mg/m(2) 3‐hour infusion; AT)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Doxorubicin-cyclophosphamide regimen (AC; 60/600 mg/m(2))
Number of subjects: 275
Study: 10664499

Group type: EXPERIMENTAL
Intervention: HBOC (60 g for initial transfusion, with options for three more doses of 30 g each within 96 hours)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Allogenic RBC transfusion (standard RBC transfusions)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HBOC
Number of subjects: 72

Group type: COMPARATOR
Intervention: Allogenic RBC
Number of subjects: 72
Study: 9038445

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 36

Group type: COMPARATOR
Intervention: 35% oxygen by facemask
Number of subjects: 36
Study: 1736766

Group type: EXPERIMENTAL
Intervention: Yogurt containing Lactobacillus acidophilus
Number of subjects: 21

Group type: COMPARATOR
Intervention: Yogurt-free diet (Control)
Number of subjects: 21
Study: 6238910

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (25 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Severe restriction of salt intake (about 1016 mg Na+/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified, but implied to be no treatment during initial 2 weeks)
Number of subjects: 0
Study: 31467047

Group type: EXPERIMENTAL
Intervention: Maternity waiting home (MWH) use
Number of subjects: 3784

Group type: EXPERIMENTAL
Intervention: Housewives
Number of subjects: 3784

Group type: EXPERIMENTAL
Intervention: Women with companions for facility visits
Number of subjects: 3784

Group type: EXPERIMENTAL
Intervention: Wealthier households (fourth vs first quintile)
Number of subjects: 3784

Group type: EXPERIMENTAL
Intervention: Women living >30 min from a health facility
Number of subjects: 3784

Group type: EXPERIMENTAL
Intervention: Education, decision-making autonomy, community-level institutional births
Number of subjects: 3784
Study: 29901599

Group type: EXPERIMENTAL
Intervention: Kinesiology tape applied from origin to insertion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Kinesiology tape applied from insertion to origin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 18
Study: 27125273

Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal polysaccharide nontypeable Haemophilus influenzae protein D-conjugated vaccine (PHiD-CV)
Number of subjects: 5093

Group type: COMPARATOR
Intervention: Control vaccine (hepatitis B)
Number of subjects: 5093
Study: 24767554

Group type: EXPERIMENTAL
Intervention: WaveOne (Dentsply Maillefer)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Reciproc (VDW)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ProTaper (Dentsply Maillefer)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mtwo (VDW)
Number of subjects: 48
Study: 22285545

Group type: EXPERIMENTAL
Intervention: DepoFoam bupivacaine 133 mg
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: DepoFoam bupivacaine 266 mg
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: DepoFoam bupivacaine 399 mg
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: DepoFoam bupivacaine 532 mg
Number of subjects: 138

Group type: COMPARATOR
Intervention: bupivacaine HCl 150 mg
Number of subjects: 138
Study: 20385935

Group type: EXPERIMENTAL
Intervention: Lutein 12 mg daily plus vitamin A 15,000 IU/d
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control tablet plus vitamin A 15,000 IU/d
Number of subjects: 225
Study: 17535827

Group type: EXPERIMENTAL
Intervention: Systemic methyl prednisolone (Group B)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (Group C)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 99
Study: 16214917

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet (18 g/1,000 kcal, 3.5 servings of fruits and vegetables/1,000 kcal, 20% energy)
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: NSAID use
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet among non-NSAID users
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet among males who did not use NSAIDs
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet among NSAID users
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet among females who did not use NSAIDs
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet among females who used NSAIDs
Number of subjects: 1905

Group type: COMPARATOR
Intervention: NSAID use in control group
Number of subjects: 1905

Group type: EXPERIMENTAL
Intervention: NSAID use in intervention group
Number of subjects: 1905
Study: 12142861

Group type: EXPERIMENTAL
Intervention: Pycnogenol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10204898

Group type: EXPERIMENTAL
Intervention: 0.5% articaine
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.5% prilocaine
Number of subjects: 10
Study: 8610766

Group type: EXPERIMENTAL
Intervention: Closed vaginal vault with two layers of continuous 3‐0 polyglactin suture
Number of subjects: 273

Group type: COMPARATOR
Intervention: Open vaginal vault with a locking 3‐0 polyglactin suture
Number of subjects: 273
Study: 2126131

Group type: EXPERIMENTAL
Intervention: KTP/532-laser tonsillectomy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Traditional dissection/snare tonsillectomy
Number of subjects: 83
Study: 434430

Group type: EXPERIMENTAL
Intervention: Respiratory gases optimally warmed and humidified
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Warming up all perfused liquids in a water‐bath heat‐exchanger
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Fenwal heat-exchanger
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 31451273

Group type: EXPERIMENTAL
Intervention: SUITENA™ (a sweetener containing erythritol, xylitol, and Stevia)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dextrose solution (control)
Number of subjects: 6
Study: 28103570

Group type: EXPERIMENTAL
Intervention: Extreme Learning Machine (ELM) for density estimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cumulative distribution function estimation algorithm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probability density function estimation algorithm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: F-discrepancy concept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theoretical analysis of ELM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation tests
Number of subjects: 0
Study: 24471477

Group type: EXPERIMENTAL
Intervention: FSK0808 (200 µg/m² intravenous dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gran® (200 µg/m² intravenous dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FSK0808 (400 µg/m² subcutaneous dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gran® (400 µg/m² subcutaneous dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FSK0808 and Gran® (secondary endpoints)
Number of subjects: 0
Study: 23871271

Group type: EXPERIMENTAL
Intervention: Bazedoxifene (BZA) 20mg
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Bazedoxifene (BZA)
Number of subjects: 1000
Study: 21976613

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids, γ-linolenic acid, and antioxidants
Number of subjects: 272

Group type: COMPARATOR
Intervention: Isocaloric control
Number of subjects: 272
Study: 19076546

Group type: EXPERIMENTAL
Intervention: SLIT 300IR
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: SLIT 500IR
Number of subjects: 628

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 628
Study: 16737371

Group type: EXPERIMENTAL
Intervention: Italians (Study 1 and 2)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Italians (Study 3 and 4)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Japanese (Study 3)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Japanese (Study 4)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Both languages (Study 5)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Japanese participants (Study 5)
Number of subjects: 416
Study: 12975689

Group type: EXPERIMENTAL
Intervention: Acamprosate (six tablets of 333 mg/d for 12 weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (six tablets for 12 weeks)
Number of subjects: 75
Study: 10636143

Group type: EXPERIMENTAL
Intervention: Estrogen (ethinyl estradiol, 25 ng/kg/d) for 1 to 3 years (mean, 2.1+/‐0.9 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen (ethinyl estradiol, 25 ng/kg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (age-matched female controls)
Number of subjects: 0
Study: 8741718

Group type: EXPERIMENTAL
Intervention: 5 sessions of applied tension (AT5)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 session of applied tension (AT1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1 session of tension-only (T1)
Number of subjects: 30
Study: 1394816

Group type: EXPERIMENTAL
Intervention: Adriamycin (ADM) intravesical instillation therapy
Number of subjects: 0
Study: 3935204

Group type: EXPERIMENTAL
Intervention: Sustained release choline theophyllinate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 29981855

Group type: EXPERIMENTAL
Intervention: Parent feedback via the Communication Assessment Tool (CAT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no parent feedback)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Combined scores of both intervention and control groups
Number of subjects: 68
Study: 29549007

Group type: EXPERIMENTAL
Intervention: Brief Advice
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Rate Reduction (including nicotine replacement therapy in the form of gum)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing plus Rate Reduction combined
Number of subjects: 840
Study: 26811156

Group type: EXPERIMENTAL
Intervention: UGT1A1 genotyping with irinotecan dose escalation
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional biweekly FOLFIRI regimen without UGT1A1 genotyping
Number of subjects: 400
Study: 25342896

Group type: EXPERIMENTAL
Intervention: Single-set resistance training (1-SET)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Three-set resistance training (3-SET)
Number of subjects: 30
Study: 21997547

Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 420
Study: 20502405

Group type: EXPERIMENTAL
Intervention: FRAX™ method
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: History of vertebral fractures
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Other fractures considered
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Densitometry results
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: SQM assessment
Number of subjects: 94
Study: 17478952

Group type: EXPERIMENTAL
Intervention: Continuous pump infusion of 0.75% ropivacaine (12 mL initial dose, 6 mL/hour thereafter) in Group A
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional injection of 0.75% ropivacaine (15 mL initial dose, 6 mL injected 80 min later) in Group B
Number of subjects: 60
Study: 16235667

Group type: EXPERIMENTAL
Intervention: GCF-glucose monitor; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; normal subjects and diabetic subjects were evaluated.
Number of subjects: 0
Study: 12117087

Group type: EXPERIMENTAL
Intervention: 0.5% fluorouracil cream (once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5% fluorouracil cream (twice daily)
Number of subjects: 0
Study: 11374329

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Treatment regimen (capsule each night, as needed, or every third night)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Self-rated sleep
Number of subjects: 64
Study: 9757979

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 113

Group type: COMPARATOR
Intervention: Nonteratogens (Control)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Histamine blockers (Disease-paired Control)
Number of subjects: 113
Study: 8165534

Group type: EXPERIMENTAL
Intervention: Gastrografin (100 ml administered through nasogastric tube)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (conventional methods)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Gastrografin
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study: 3144198

Group type: COMPARATOR
Intervention: Nasal oxygen flow at 0 L/min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nasal oxygen flow at 2 L/min
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nasal oxygen flow at 4 L/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Topical lidocaine application
Number of subjects: 8
Study: 29523049

Group type: EXPERIMENTAL
Intervention: Exercise before the learning task
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Exercise after the learning task
Number of subjects: 33

Group type: COMPARATOR
Intervention: Only learning task
Number of subjects: 33
Study: 28439596

Group type: EXPERIMENTAL
Intervention: Laparoscopic operation (LP)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Open operation (OP)
Number of subjects: 206
Study: 26234554

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation plus diaphragm pacing with the NeuRx RA/4 Diaphragm Pacing System
Number of subjects: 74

Group type: COMPARATOR
Intervention: Non-invasive ventilation alone
Number of subjects: 74
Study: 24093880

Group type: EXPERIMENTAL
Intervention: Adaptive working memory training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-adaptive working memory training with low memory loads
Number of subjects: 0

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 0
Study: 21570069

Group type: EXPERIMENTAL
Intervention: Adjuvant acupuncture for IVF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham acupuncture control
Number of subjects: 0
Study: 18670391

Group type: EXPERIMENTAL
Intervention: Bronchoscopy (Group I)
Number of subjects: 179

Group type: COMPARATOR
Intervention: FNAB or tumour wedge resection by VATS (Group II)
Number of subjects: 179
Study: 17146316

Group type: EXPERIMENTAL
Intervention: Chromium supplementation (600 microg/d as picolinate)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16